A lead discovery strategy driven by a comprehensive analysis of proteases in the peptide substrate space

Protein Science

Volumn 19, Issue 11, 2010, Pages 2096-2109

  Sukuru, Sai Chetan K ^a,c   Nigsch, Florian ^a   Quancard, Jean ^b   Renatus, Martin ^b   Chopra, Rajiv ^a   Brooijmans, Natasja ^a   Mikhailov, Dmitri ^a   Deng, Zhan ^a   Cornett, Allen ^a   Jenkins, Jeremy L ^a   Hommel, Ulrich ^b   Davies, John W ^a   Glick, Meir ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PFIZER INC   (United States)

Author keywords

Chemical space; In silico; Lead discovery; Proteases; Substrate space

Indexed keywords

ASPARTIC ACID; CALPAIN 1; CASPASE 3; CATHEPSIN V; CYSTEINE; CYSTEINE PROTEINASE; GELATINASE B; GRANZYME B; OCTAPEPTIDE; PEPSIN A; PROTEINASE; SERINE; SERINE PROTEINASE;

ARTICLE; BAYES THEOREM; ENZYME ACTIVE SITE; ENZYME ANALYSIS; ENZYME SUBSTRATE COMPLEX; MOLECULAR MODEL; PRIORITY JOURNAL; PROTEIN FAMILY; RELIABILITY;

ANIMALS; BACTERIAL PROTEINS; BAYES THEOREM; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; HUMANS; OLIGOPEPTIDES; PEPTIDE HYDROLASES; PROTEIN STRUCTURE, TERTIARY; RATS; REPRODUCIBILITY OF RESULTS; VIRAL PROTEINS;

EID: 78349248588     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.490     Document Type: Article

References (42)

1. Johnson MA, Maggiora GM (1990) Concepts and applications of molecular similarity. New York: Wiley.
2. Jacoby E, Schuffenhauer A, Floersheim P (2003) Chemogenomics knowledge-based strategies in drug discovery. Drug News Perspect 16:93-102. (Pubitemid 36749735)
3. Harris CJ, Stevens AP (2006) Chemogenomics: structuring the drug discovery process to gene families. Drug Discov Today 11:880-888.
4. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H (2004) Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta 1697:243-257. (Pubitemid 38326776)
5. Puente XS, Sanchez LM, Overall CM, Lopez-Otin C (2003) Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 4:544-558. (Pubitemid 36781345)
6. Turk B (2006) Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 5:785-799. (Pubitemid 44323703)
7. Lopez-Otin C, Bond JS (2008) Proteases: multifunctional enzymes in life and disease. J Biol Chem 283:30433-30437.
8. Rawlings ND, Morton FR, Kok CY, Kong J, Barrett AJ (2008) MEROPS: the peptidase database. Nucleic Acids Res 36:D320-D325.
9. Schechter I, Berger A (1967) On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 27:157-162.
10. Nidhi Glick M, Davies JW, Jenkins JL (2006) Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J Chem Inf Model 46:1124-1133.
11. Ansarah-Sobrinho C, Moss B (2004) Role of the I7 protein in proteolytic processing of vaccinia virus membrane and core components. J Virol 78:6335-6343. (Pubitemid 38715932)
12. Byrd CM, Bolken TC, Hruby DE (2003) Molecular dissection of the vaccinia virus I7L core protein proteinase. J Virol 77:11279-11283.
13. Wu S, Lim KC, Huang J, Saidi RF, Sears CL (1998) Bacteroides fragilis enterotoxin cleaves the zonula adherens protein, E-cadherin. Proc Natl Acad Sci USA 95:14979-14984. (Pubitemid 29003742)
14. Holton J (2008) Enterotoxigenic Bacteroides fragilis. Curr Infect Dis Rep 10:99-104.
15. Lakhani SA, Masud A, Kuida K, Porter GA, Jr, Booth CJ, Mehal WZ, Inayat I, Flavell RA (2006) Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 311:847-851. (Pubitemid 43228848)
16. Demon D, Van Damme P, Vanden Berghe T, Deceuninck A, Van Durme J, Verspurten J, Helsens K, Impens F, Wejda M, Schymkowitz J, Rousseau F, Madder A, Vandekerckhove J, Declercq W, Gevaert K, Vandenabeele P (2009) Proteome-wide substrate analysis indicates substrate exclusion as a mechanism to generate caspase-7 versus caspase-3 specificity.Mol Cell Proteomics 8:2700-2714.
17. Walsh JG, Cullen SP, Sheridan C, Luthi AU, Gerner C, Martin SJ (2008) Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci USA 105:12815-12819.
18. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW (1997) A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 272:17907-17911.
19. MacNeill AL, Turner PC, Moyer RW (2006) Mutation of the Myxoma virus SERP2 P1-site to prevent proteinase inhibition causes apoptosis in cultured RK-13 cells and attenuates disease in rabbits, but mutation to alter specificity causes apoptosis without reducing virulence. Virology 356:12-22.
20. Willoughby CA, Bull HG, Garcia-Calvo M, Jiang J, Chapman KT, Thornberry NA (2002) Discovery of potent, selective human granzyme B inhibitors that inhibit CTL mediated apoptosis. Bioorg Med Chem Lett 12:2197-2200.
21. Fang B, Fu G, Agniswamy J, Harrison RW, Weber IT (2009) Caspase-3 binds diverse P4 residues in peptides as revealed by crystallography and structural modeling. Apoptosis 14:741-752.
22. Rotonda J, Garcia-Calvo M, Bull HG, Geissler WM, McKeever BM, Willoughby CA, Thornberry NA, Becker JW (2001) The three-dimensional structure of human granzyme B compared to caspase-3, key mediators of cell death with cleavage specificity for aspartic acid in P1. Chem Biol 8:357-368.
23. Leung D, Abbenante G, Fairlie DP (2000) Protease inhibitors: current status and future prospects. J Med Chem 43:305-341.
24. Abbenante G, Fairlie DP (2005) Protease inhibitors in the clinic. Med Chem 1:71-104.
25. Becker JW, Rotonda J, Soisson SM, Aspiotis R, Bayly C, Francoeur S, Gallant M, Garcia-Calvo M, Giroux A, Grimm E, Han Y, McKay D, Nicholson DW, Peterson E, Renaud J, Roy S, Thornberry N, Zamboni R (2004) Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis. J Med Chem 47:2466-2474.
26. Komoriya S, Kobayashi S, Osanai K, Yoshino T, Nagata T, Haginoya N, Nakamoto Y, Mochizuki A, Nagahara T, Suzuki M, Shimada T, Watanabe K, Isobe Y, Furugoori T (2006) Design, synthesis, and biological activity of novel factor Xa inhibitors: improving metabolic stability by S1 and S4 ligand modification. Bioorg Med Chem 14:1309-1330.
27. Jagarlapudi SA, Kishan KV (2009) Database systems for knowledge-based discovery. Methods Mol Biol 575:159-172.
28. Glick M, Klon AE, Acklin P, Davies JW (2004) Enrichment of extremely noisy high-throughput screening data using a naive Bayes classifier. J Biomol Screen 9:32-36.
29. Xia X, Maliski EG, Gallant P, Rogers D (2004) Classification of kinase inhibitors using a Bayesian model. J Med Chem 47:4463-4470.
30. Santamaria I, Velasco G, Cazorla M, Fueyo A, Campo E, Lopez-Otin C (1998) Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Res 58:1624-1630. (Pubitemid 28215082)
31. Yu Q, Stamenkovic I (2000) Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 14:163-176.
32. Kageyama T (2002) Pepsinogens, progastricsins, and prochymosins: structure, function, evolution, and development. Cell Mol Life Sci 59:288-306.
33. Scheiber J, Chen B, Milik M, Sukuru SC, Bender A, Mikhailov D, Whitebread S, Hamon J, Azzaoui K, Urban L, Glick M, Davies JW, Jenkins JL (2009) Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model 49:308-317.
34. Rao BG (2005) Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 11:295-322.
35. Casbarra A, Piaz FD, Ingallinella P, Orru S, Pucci P, Pessi A, Bianchi E (2002) The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure. Protein Sci 11:2102-2112.
36. Niyomrattanakit P, Yahorava S, Mutule I, Mutulis F, Petrovska R, Prusis P, Katzenmeier G, Wikberg JE (2006) Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides. Biochem J 397:203-211.
37. Ng NM, Pike RN, Boyd SE (2009) Subsite cooperativity in protease specificity. Biol Chem 390:401-407.
38. Tyndall JD, Nall T, Fairlie DP (2005) Proteases universally recognize beta strands in their active sites. Chem Rev 105:973-999. (Pubitemid 40527381)
39. Rogers D, Hahn M (2010) Extended-connectivity fingerprints. J Chem Inf Model 50:742-754.
40. Triballeau N, Acher F, Brabet I, Pin JP, Bertrand HO (2005) Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to high-throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 48:2534-2547.
41. Felsenstein J (2005) PHYLIP (Phylogeny Inference Package) version 3.68. Distributed by the author. Department of Genome Sciences, University of Washington, Seattle.
42. Jordan GE, Piel WH (2008) PhyloWidget: web-based visualizations for the tree of life. Bioinformatics 24:1641-1642.